Table 2.
Baseline and interview characteristics associated with disease progression for the participants in the LISA cohort.
| Factors | CD4+/pVL+ (Best) N = 196 |
CD4+ /pVL− or CD4−/pVL+ (Incomplete) N = 180 |
CD4− /pVL− (Worst) N = 161 |
p-value |
|---|---|---|---|---|
| CAGE Questionnaire Results | ||||
| No indication of having a history of alcoholism | 107 (55%) | 95 (53%) | 50 (31%) | <0.0001 |
| Indication of having a history of alcoholism | 63 (32%) | 53 (29%) | 47 (29%) | |
| Confirmed history of alcoholism | 26 (13%) | 32 (18%) | 64 (40%) | |
| CAGE & History of injection drug use | ||||
| No history of alcohol and injection drug use | 48 (24%) | 38 (21%) | 14 (9%) | <0.0001 |
| History of alcohol or injection drug use | 125 (64%) | 114 (63%) | 86 (53%) | |
| History of both alcohol and injection drug use | 23 (12%) | 28 (16%) | 61 (38%) | |
| Sex | ||||
| Male | 164 (84%) | 132 (73%) | 100 (62%) | <.0001 |
| Female | 32 (16%) | 48 (27%) | 61 (38%) | |
| History of injection drug use | ||||
| No | 68 (35%) | 56 (31%) | 21 (13%) | <.0001 |
| Yes | 128 (65%) | 124 (69%) | 140 (87%) | |
| Baseline HAART regimen | ||||
| Unboosted PI | 39 (20%) | 49 (27%) | 47 (29%) | 0.0022 |
| Boosted PI | 83 (42%) | 52 (29%) | 37 (23%) | |
| NNRTI | 74 (38%) | 79 (44%) | 77 (48%) | |
| Adherence to HAART (6 months before interview) | ||||
| ≥95% | 159 (81%) | 142 (79%) | 63 (39%) | <0.0001 |
| <95% | 37 (19%) | 38 (21%) | 98 (61%) | |
| Baseline age (years) | 42 (36 – 48) | 42 (34 – 48) | 38 (32 – 43) | <0.0001 |
| CD4 cell count (cells/mm3) | ||||
| Baseline | 120 (40 – 180) | 240 (150 – 360) | 260 (180 – 420) | <0.0001 |
| At the time of interview | 435 (315 – 670) | 400 (260 – 575) | 240 (140 – 350) | <0.0001 |
| • Percent change from baseline | 291 (150 – 650) | 58 (10 – 138) | −12 (−43 – 26) | <0.0001 |
| • Difference from baseline | 320 (220 – 500) | 140 (30 – 265) | −20 (−140 – 50) | <0.0001 |
| Plasma Viral Load (log 10 copies/mL) | ||||
| Baseline | 5.0 (5.0 – 5.0) | 5.0 (4.7 – 5.0) | 4.4 (4.0 – 4.7) | <0.0001 |
| • Difference from baseline | −2.3 (−2.3 – −2.3) | −2.2 (−2.3 – −1.8) | −0.8 (−1.5 – 0) | <0.0001 |
| Follow-up from baseline to the interview (year) | 4.3 (2.2 – 7.3) | 5.1 (1.9 – 8.9) | 6.5 (2.5 – 6.1) | 0.0609 |
NNRTI: non-nucleoside reverse transcriptase inhibitor; Boosted PI: protease inhibitor boosted with ≤400mg/day ritonavir; Unboosted PI: single protease inhibitor; pVL: Viral load.